Chen H et al. (2013), Comparison of the effects of antiarrhythmic dru...

XB-ART-46301

Acta Pharmacol Sin 2013 Feb 01;342:221-30. doi: 10.1038/aps.2012.157.

Show Gene links Show Anatomy links

Comparison of the effects of antiarrhythmic drugs flecainide and verapamil on fKv1.4ΔN channel currents in Xenopus oocytes.

Chen H , Zhang D , Chao SP , Ren JH , Xu L , Jiang XJ , Wang SM .

???displayArticle.abstract???
To study the effects of Na(+) channel blocker flecainide and L-type Ca(2+) channel antagonist verapamil on the voltage-gated fKv1.4ΔN channel, an N-terminal-deleted mutant of the ferret Kv1.4 K(+) channel. fKv1.4ΔN channels were stably expressed in Xenopus oocytes. The K(+) currents were recorded using a two-electrode voltage-clamp technique. The drugs were administered through superfusion. fKv1.4ΔN currents displayed slow inactivation, with a half-inactivation potential of -41.74 mV and a slow recovery from inactivation (τ=1.90 s at -90 mV). Flecainide and verapamil blocked the currents with IC(50) values of 512.29 ± 56.92 and 260.71 ± 18.50 μmol/L, respectively. The blocking action of the drugs showed opposite voltage-dependence: it was enhanced with depolarization for flecainide, and was attenuated with depolarization for verapamil. Both the drugs exerted state-dependent blockade on fKv1.4ΔN currents, but verapamil showed a stronger use-dependent blockage compared with flecainide. Flecainide accelerated the C-type inactivation rate without affecting the recovery kinetics and the steady-state activation. Verapamil also accelerated the inactivation kinetics of the currents, but unlike flecainide, it affected both the recovery and the steady-state activation, causing slower recovery of fKv1.4ΔN channel and a depolarizing shift of the steady-state activation curve. The results demonstrate that widely used antiarrhythmic drugs flecainide and verapamil substantially inhibit fKv1.4ΔN channels expressed in Xenopus oocytes by binding to the open state of the channels. Therefore, caution should be taken when these drugs are administered in combination with K(+) channel blockers to treat arrhythmia.

???displayArticle.pubmedLink??? 23202797
???displayArticle.pmcLink??? PMC4011620
???displayArticle.link??? Acta Pharmacol Sin

Species referenced: Xenopus
Genes referenced: kcna4 tff3.7

???attribute.lit??? ???displayArticles.show???

	Figure 1. Effects of flecainide and verapamil on the fKv1.4ÎN channel expressed in Xenopus oocytes. Representative curves were shown for 5 s depolarizing steps from â90 mV to voltages between â100 and +50 mV in steps of 10 mV. (A and B) Traces recorded under control conditions. (C and D) Current traces obtained in the presence of 500 Î¼mol/L flecainide (C) or 250 Î¼mol/L verapamil (D). (E and F) Effects of 500 Î¼mol/L flecainide (E) or 250 Î¼mol/L verapamil (F) on the peak current-voltage (IâV) relationships. Currents were normalized to the peak current at +50 mV under control conditions. The Idrug/Icontrol ratio was plotted as a function of the membrane potential. Data are shown as meanÂ±SEM (n=5).
	Figure 2. Concentration-response relationships for the inhibition of the fKv1.4ÎN currents by flecainide and verapamil. (A and B) Representative current traces were elicited in the absence and presence of increasing concentrations of flecainide (A) or verapamil (B). Currents were recorded by depolarizing steps to +50 mV from a holding potential of â90 mV. (C and D) The peak currents were normalized to the maximum peak current under control conditions and plotted against flecainide (C) and verapamil (D) concentrations. The curves were derived by fitting data to the Hill equation. Symbols and error bar are meanÂ±SEM (n=5).
	Figure 3. Use-dependent block of the fKv1.4ÎN currents by flecainide and verapamil. (A and B) Sixty repetitive depolarizing steps from â90 to +50 mV for 500 ms each were applied in the absence and presence of flecainide (A) or verapamil (B). (C and D) Each peak current was normalized to the peak current at the first step under control conditions and then plotted against the number of steps. Data are shown as meanÂ±SEM (n=5).
	Figure 4. Effects of flecainide and verapamil on the activation of the fKv1.4ÎN currents. (AâD) Current traces were obtained by applying 80 ms steps to potentials ranging from â100 to +50 mV and were followed by the tail currents obtained upon repolarization to â40 mV in the absence (A and B) and presence of 500 Î¼mol/L flecainide (C) or 250 Î¼mol/L verapamil (D). (E and F) Peak current activation relationships in the absence and presence of 500 Î¼mol/L flecainide (E) and 250 Î¼mol/L verapamil (F). The steady-state activation curves were depicted by plotting the peak tail currents (obtained at â40 mV) against the depolarizing potentials (from â100 to +50 mV). Continuous lines represent the fit of the data to a Boltzmann equation: f=1/{1+exp*[(VâV1/2)/k)]}. Average data are shown as meanÂ±SEM (n=5).
	Figure 5. Changes in the inactivation kinetic properties of the fKv1.4ÎN currents by flecainide and verapamil. (A and B) Steady-state inactivation was studied using a two-step voltage protocol, currents were measured at +50 mV, and the 5 s pre-steps to potential varied from â100 to +50 mV in steps of 10 mV. The curves for steady-state inactivation were fitted with the Boltzmann equation: I/Imax=(1âÎ±)/{1+exp*[(VâV1/2)/k)]}+Î±. (C and D) Time constant of inhibition as a function of the drug concentration. Time constants (Ïblock) were estimated from a single or double exponential fits to the tracings shown in Figure 1. The apparent rate constants for association (k+1) and dissociation (k-1) were obtained from the equation: 1/Ïblock=k+1[d]+kâ1 (n=5). Data are shown as meanÂ±SEM (n=5).
	Figure 6. Effects of flecainide and verapamil on the kinetics of the fKv1.4ÎN channel recovery from steady-state inactivation. The degree of recovery was measured by following a standard variable interval gapped step protocol. An initial 5 s step (P1) from â90 to +50 mV was followed by a second step (P2) to +50 mV after an interval of between 0.1 and 20 s. (A and B) Current traces were elicited in the absence of flecainide (A) or verapamil (B). (C and D) Current traces obtained in the presence of 500 Î¼mol/L flecainide (C) or 250 Î¼mol/L verapamil (D). (E and F) The ratio of the peak current elicited by the P1 and P2 steps (P2/P1) is plotted as a function of the various interstep intervals. The continuous line represents the fit of the data to the equation: f=1âA*exp(âÏ/t). Data were normalized between 0 and 1 presented with intervals on a log scale. Data are shown as meanÂ±SEM (n=5).

References [+] :

Anderson, Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. 1989, Pubmed
Bodi, Electrical remodeling in hearts from a calcium-dependent mouse model of hypertrophy and failure: complex nature of K+ current changes and action potential duration. 2003, Pubmed
Brahmajothi, Distinct transient outward potassium current (Ito) phenotypes and distribution of fast-inactivating potassium channel alpha subunits in ferret left ventricular myocytes. 1999, Pubmed
Caballero, Diltiazem inhibits hKv1.5 and Kv4.3 currents at therapeutic concentrations. 2004, Pubmed
Caballero, Effects of flecainide and quinidine on Kv4.2 currents: voltage dependence and role of S6 valines. 2003, Pubmed
Choi, Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells. 2000, Pubmed
Comer, Cloning and characterization of an Ito-like potassium channel from ferret ventricle. 1994, Pubmed , Xenbase
Grossman, Calcium antagonists. 2004, Pubmed
Henthorn, Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. 1991, Pubmed
Hoshi, Biophysical and molecular mechanisms of Shaker potassium channel inactivation. 1990, Pubmed , Xenbase
Kaprielian, Relationship between K+ channel down-regulation and [Ca2+]i in rat ventricular myocytes following myocardial infarction. 1999, Pubmed
Ko, Calcium channel inhibitor, verapamil, inhibits the voltage-dependent K+ channels in rabbit coronary smooth muscle cells. 2010, Pubmed
Liu, Dynamic rearrangement of the outer mouth of a K+ channel during gating. 1996, Pubmed
Matsubara, Shaker-related potassium channel, Kv1.4, mRNA regulation in cultured rat heart myocytes and differential expression of Kv1.4 and Kv1.5 genes in myocardial development and hypertrophy. 1993, Pubmed
Milberg, Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. 2005, Pubmed
Nishiyama, Altered K(+) channel gene expression in diabetic rat ventricle: isoform switching between Kv4.2 and Kv1.4. 2001, Pubmed
Park, The protein kinase C inhibitor, bisindolylmaleimide (I), inhibits voltage-dependent K+ channels in coronary arterial smooth muscle cells. 2005, Pubmed
Paul, Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. 2002, Pubmed
Ramos, State-dependent trapping of flecainide in the cardiac sodium channel. 2004, Pubmed , Xenbase
Rampe, Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart. 1993, Pubmed
Rasmusson, C-type inactivation controls recovery in a fast inactivating cardiac K+ channel (Kv1.4) expressed in Xenopus oocytes. 1995, Pubmed , Xenbase
Rasmusson, Inactivation of voltage-gated cardiac K+ channels. 1998, Pubmed
Roden, Current status of class III antiarrhythmic drug therapy. 1993, Pubmed
Slawsky, K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. 1994, Pubmed
Snyders, A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. 1993, Pubmed
Snyders, Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. 1992, Pubmed
Wang, State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide. 2003, Pubmed
Wang, Kv1.4 channel block by quinidine: evidence for a drug-induced allosteric effect. 2003, Pubmed , Xenbase
Wang, Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation. 1997, Pubmed , Xenbase
Wickenden, Regional contributions of Kv1.4, Kv4.2, and Kv4.3 to transient outward K+ current in rat ventricle. 1999, Pubmed
Xu, Effect of amiodarone on Kv1.4 channel C-type inactivation: comparison of its effects with those induced by propafenone and verapamil. 2008, Pubmed , Xenbase
Yamagishi, Antiarrhythmic and bradycardic drugs inhibit currents of cloned K+ channels, KV1.2 and KV1.4. 1995, Pubmed , Xenbase
Zhang, Effects of diltiazem and propafenone on the inactivation and recovery kinetics of fKv1.4 channel currents expressed in Xenopus oocytes. 2011, Pubmed , Xenbase
Zhang, Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. 1999, Pubmed